Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients

doi:10.3748/wjg.v24.i28.3171

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8125)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

756

HTML

4632

Figures (1-1)

276

Tables (1-4)

246

Sum=5910

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1025

Download

1190

Sum=2215

Jul 28, 2018 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Gastroenterol. Jul 28, 2018; 24(28): 3171-3180
Published online Jul 28, 2018. doi: 10.3748/wjg.v24.i28.3171

Table 4 Primary outcomes of study cohorts comparing liver transplantation recipients with and without recurrent primary sclerosing cholangitis in the liver graft

Ref.	Year	Presence of IBD(ever)	*Time of IBD diagnosis (pre-LT/de novo)*	Presence of IBD (post-LT)	Time of colectomypre- and peri-LT/post-LT	Type of colectomy	Primary immunosuppression	Secondary immunosuppression
¹Cholongitas et al[21]	2008	7 (100) vs 26 (56)	5 (71)/2 (29) vs 25 (54)/1 (2)	7 (100) vs 26 (56)	0 (0)/1 (14) vs 6 (13)/6 (13)	NR	TAC 2 (29) vs 25 (54) CyA 5 (71) vs 21 (46)	AZA 3 (43) vs 22 (48) OKT3 or ATG 2 (29) vs 11 (24)
Alabraba et al[20]	2009	39 (72) vs 123 (70)	NR	NR	1 (2)/14 (23) vs 28 (16)/18 (10)	Panproctocolectomy 7 (13) vs 15 (8) Segmental + subtotal 5 (9) vs 21 (12) Ileoanal pouch 3 (6) vs 10 (6)	TAC 16 (26) vs 104 (51) CyA 44 (72) vs 95 (47)	None 1 (2) vs 3 (2) OKT3 0 (0) vs 2 (2)
Moncrief et al[24]	2010	15 (100) vs 33 (75)	11 (73)/4 (27) vs 31 (70)/2 (5)	13 (87) vs 24 (55)	1 (7)/NR vs 9 (20)/NR	NR	TAC 7 (47) vs 28 (64) CyA 8 (53) vs 14 (32)	NR
Gelley et al[22]	2014	6 (100) vs 15 (79)	5 (83)/1 (17) vs 14 (74)/1 (5)	6 (100) vs 15 (79)	0 (0)/2 (34) vs 4 (21)/2 (11)	NR	TAC 4 (67) vs 14 (74) CyA 2 (33) vs 5 (26)	NR
¹Ravikumar et al[25]	2015	51 (78) vs 220 (52)	42 (65)/9 (13) vs 193 (46)/27 (6)	43 (66) vs 181 (42)	5 (6)/14 (17) vs 40 (8)/46 (10)	Panproctocolectomy: 2 (2) vs 22 (5) Segmental + subtotal: 16 (20) vs 41 (8) Other: 1 (1) vs 17 (4)	TAC 36 (44) vs 330 (68) CyA 20 (25) vs 55 (11)	AZA 26 (32) vs 212 (44) MMF 10 (12) vs 67 (14) Steroids 38 (47) vs 285 (59)
Hildebrand et al[23]	2016	53 (86) vs 167 (71)	NR	48 (77) vs 138 (59)	NR	NR	TAC 41 (67) vs 150 (66) CyA 32 (53) vs 124 (55)	Steroids 41 (70) vs 133 (60)

Data are expressed as n (%).

¹Studies reporting exclusively on ulcerative colitis. ATG: Anti-thymocyte globulin; AZA: Azathioprine; CyA: Cyclosporine A; IBD: Inflammatory bowel disease; LT: Liver transplantation; MMF: Mycophenolate mofetil; NR: Not reported; OKT3: Muromonab-CD3; TAC: Tacrolimus.

Citation: Buchholz BM, Lykoudis PM, Ravikumar R, Pollok JM, Fusai GK. Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. World J Gastroenterol 2018; 24(28): 3171-3180
URL: https://www.wjgnet.com/1007-9327/full/v24/i28/3171.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i28.3171